A Potential Therapeutic Effect of Suxiao Jiuxin Pills in Treating Postacute Sequelae of COVID-19: Case Report

Abstract

Postacute Sequelae of COVID-19 Cardiovascular Syndrome (PASC-CVS) refers to a broad spectrum of cardiovascular symptoms that manifest four weeks or more after infection with COVID-19, which cannot be diagnosed as cardiovascular disease through standard examinations. Common symptoms include exercise intolerance and tachycardia, alongside persistent issues such as chest pain, chest tightness, and difficulty breathing. PASC-CVS significantly affects patients’ quality of life; however, effective treatments for this condition are currently lacking. In this report, we present two cases of PASC-CVS patients who experienced well-controlled cardiovascular symptoms following treatment with Suxiao Jiuxin Pills. Our findings may offer a novel approach to the clinical management of PASC-CVS.